New drug cocktail aims to stop kidney rejection in transplant patients
NCT ID NCT02201576
First seen Feb 15, 2026 · Last updated May 31, 2026 · Updated 16 times
Summary
This study tested whether a drug called bortezomib, given with steroids, plasma exchange, and immunoglobulins, can treat chronic antibody-mediated rejection in kidney transplant recipients. The trial included 60 adults who had a kidney transplant and developed donor-specific antibodies. The goal was to see if this combination could reduce signs of rejection in kidney tissue and lower harmful antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC ANTIBODY-MEDIATED TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Necker Enfants-malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.